Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Sep 15;119(18):3402-10.
doi: 10.1002/cncr.28217. Epub 2013 Jun 24.

Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer

Joe Y Chang  1 , Yung-Hsien Liu, Zhengfei Zhu, James W Welsh, Daniel R Gomez, Ritsuko Komaki, Jack A Roth, Stephen G Swisher
Affiliations

Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer

Joe Y Chang et al. Cancer. .

Abstract

Background: Surgical resection has been the standard treatment for early stage multiple primary lung cancer (MPLC). However, a significant proportion of patients with MPLC cannot undergo surgery. For this report, the authors explored the role of stereotactic ablative radiotherapy (SABR) for patients with MPLC.

Methods: Patients with MPLC who received SABR (50 grays [Gy] in 4 fractions or 70 Gy in 10 fractions) for the second tumor were reviewed. Four-dimensional, computed tomography-based, planning/volumetric image-guided treatment was used for all patients. Treatment outcomes/toxicities were analyzed.

Results: For the 101 patients who received SABR, at a median follow-up of 36 months and with a median overall survival (OS) of 46 months, the 2-year and 4-year in-field local control rates were 97.4% and 95.7%, respectively. The 2-year and 4-year OS rates were 73.2% and 47.5%, respectively; and the progression-free survival (PFS) rates were 67% and 58%, respectively. Patients who had metachronous tumors had better OS and PFS than patients who had synchronous tumors (2-year OS: 80.6% metachronous vs 61.5% synchronous; 4-year OS: 52.7% vs 39.7%, respectively; P = .047; 2-year PFS: 84.7% vs 49.4%, respectively; 4-year PFS: 75.6% vs 30.4%, respectively; P = .0001). For patients who either underwent surgery or received SABR for an index tumor, the incidence of grade ≥ 3 radiation pneumonitis was 3% (2 of 71 patients); however, this increased to 17% (5 of 30 patients) for those who received conventional radiotherapy for an index tumor. Other grade ≥ 3 toxicities included grade 3 chest wall pain (3 of 101 patients; 3%) and grade 3 skin toxicity (1 of 101 patients; 1%).

Conclusions: SABR achieves promising long-term tumor control and survival and may be a potential curative treatment for early stage MPLC.

Keywords: metachronous tumors; multiple primary lung cancer; stereotactic ablative radiotherapy; stereotactic body radiotherapy; synchronous tumors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival for all patients, patients with metachronous multiple primary lung cancer (MPLC), and patients with synchronous MPLC.
Figure 2
Figure 2
Progression-free survival for all patients, patients with metachronous multiple primary lung cancer (MPLC), and patients with synchronous MPLC.
Figure 3
Figure 3
Overall survival for patients whose index and second tumors were both stage I and for patients whose index tumors were of higher stage.
See this image and copyright information in PMC

References

    1. Trousse D, Barlesi F, Loundou A, et al. Synchronous multiple primary lung cancer: an increasing clinical occurrence requiring multidisciplinary management. J Thorac Cardiovasc Surg. 2007;133:1193–1200. - PubMed
    1. Aziz TM, Saad RA, Glasser J, et al. The management of second primary lung cancers. A single centre experience in 15 years. Eur J Cardiothorac Surg. 2002;21:527–533. - PubMed
    1. Rosengart TK, Martini N, Ghosn P, et al. Multiple primary lung carcinomas: prognosis and treatment. Ann Thorac Surg. 1991;52:773–778. - PubMed
    1. Rice D, Kim HW, Sabichi A, et al. The risk of second primary tumors after resection of stage I non-small-cell lung cancer. Ann Thorac Surg. 2003;76:1001–1007. - PubMed
    1. Bhaskarla A, Tang PC, Mashtare T, et al. Analysis of second primary lung cancers in the SEER database. J Surg Res. 2010;162:1–6. - PubMed

Publication types